numerous tables including:
Table 1 Patient characteristics of 16 patients with 119 brain metastases
Conclusions
Brain metastases from ovarian cancer are
rare, but their incidence is increasing as patient survival has been
extended by
successful platinum-based chemotherapy and improved
imaging techniques have enabled the identification of smaller lesions.
In our study, the median survival from brain metastases
was 12.5 months, and the local control rate was 86.4 %. The KPS and
total volume of brain metastases were important factors
predictive of survival. Our results suggest that GKS is an acceptable
therapy for brain metastases from ovarian cancer.
Conflicts of interest
None.
Open Access
